Premium
P1‐283: ROUTINE CLINICAL USE OF MASS SPECTROMETRY FOR QUANTIFICATION OF AMYLOID‐β 1‐40 AND 1‐42: PRE‐ANALYTICAL AND ANALYTICAL CONSIDERATIONS
Author(s) -
Nguyen Amy T.H.,
Grace van der Gugten J.,
Kuen Fok Alice Chui,
Robin Hsiung Ging-Yuek,
DeMarco Mari L.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.289
Subject(s) - chromatography , chemistry , elution , mass spectrometry , sample preparation , high performance liquid chromatography , extraction (chemistry) , solid phase extraction
was shown to be < 0.5 pg/mL and the LoQ < 5 pg/mL. No high dose hook effect was observed for samples containing up to 30000 pg/mL of phospho-Tau181. Linearity was shown across the clinical relevant range. A method comparison study with the INNOTEST PHOSPHO-TAU-(181P) assay demonstrated a good correlation (r>0.90). Conclusions:Automation, the mono test cartridge principle, short throughput times, and instrument flexibility are key attributes of the LUMIPULSE G instrument series making it the ideal platform to fulfill today’s needs for rapid and accurate quantification of CSF biomarkers. The novel Lumipulse G pTau 181 assay (under development) shows good sensitivity and precision, correlates well with the INNOTEST assay and completes the routine CSF biomarker panel for AD on LUMIPULSE.